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A  number of studies have shown that the presence of a  tumor in an animal 
may  alter  that  animal's  capacity  to  respond  to  immunologic  stimuli  (1-8). 
Recently, a low molecular weight factor was detected in lysates of murine tumor 
cells but not of normal  tissues.  This factor interfered with macrophage  accu- 
mulation  in  vivo  and  chemotactic  responsiveness  in  vitro  (3,  6,  7).  Since 
macrophages have been implicated as major effectors of tumor immunity (9-11), 
it was postulated that by producing this factor, tumors might escape immuno- 
logic destruction  (3, 6,  7). Indeed, it was shown that the administration  of the 
factor to mice made them more susceptible to the development of progressive 
tumors when implanted with low numbers of neoplastic cells (6). In the present 
investigation, tumor cells of common origin but different degrees of virulence in 
vivo  were  studied  to  determine  if the  ultimate  fate  of the  tumor  in  vivo 
corresponded to the ability of the cells to produce the macrophage chemotaxis 
inhibitor (MCI). 1 
Materials  and  Methods 
Tumor.  A  mouse lymphoma,  6C3HED,  which originated  in C3H mice was purchased  from 
The Jackson  Laboratory,  Bar Harbor,  Maine,  and  maintained  by serial transplantation  in the 
calf muscles of C3HeB/FeJ mice. Single cell suspensions were prepared as described (12). These 
freshly prepared cells are hereafter called virulent tumor. A tumor cell line was first adapted into 
tissue culture in 1974 (line 1) and again in 1976 (lines 2 and 3). For adaptation to tissue culture, 2 
ml of single cell suspensions  were inoculated into 12  ×  75-mm culture tubes  (Falcon Products, 
Div. Becton, Dickinson & Co., Cockeysville, Md.) at a concentration of 10  e cells/ml in RPMI-1640 
containing  10%  fetal  bovine  serum,  2  mM  L-glutamine,  100  U  penicillin/ml,  and  100  ~g 
streptemycin/ml (Microbiological Associates, Walkersville, Md.), and incubated in humidified air 
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containing 5% CO2. The cells were incubated while being monitored by periodic cell counts. Once 
consistent proliferation was detected, the culture was transferred to a  250-ml culture flask with 
sufficient medium to yield 25 ml. The cells were maintained by decanting the medium aider gentle 
agitation to remove most cells from the bottom of the flask and by adding 25 ml of fresh medium. 
New flasks were propagated by seeding them with 25 ml medium containing tumor cells at 103- 
104/ml. 
Mice.  C3HeB/FeJ  males of 8-12  wk  of age from The Jackson  Laboratory were  used in all 
tumor experiments, and for assaying MCI. 
Tumor Inoculation.  Tumor  cells  were  suspended  in  Hanks'  balanced  salt  solution  at  the 
desired concentration and injected into the calf muscles of recipient mice in a 0.05-ml volume. The 
growth of the tumors was recorded as previously described (12). 
Irradiation.  Sublethal irradiation was performed as previously described (12). 
Thymectomy of Mice.  4-wk-old C3H mice were thymectomized, irradiated with 850 rads, and 
reconstituted with bone marrow cells treated with anti-Thy 1 and complement as described (12), 
These are designated ATXBM mice. 
Preparation of Macrophage Chemotaxis Inhibitor.  Tumor cells or control tissues were  sus- 
pended to contain 5  ×  107 cells/ml in RPMI-1640.  The lysates were prepared by sonicating the 
suspensions for 2 rain followed by centrifugation for 10 rain at 12,000g. Filtrates were prepared by 
subjecting the lysates to ultrafiltration in Amicon CF25 cones (Amicon Corp., Lexington, Mass.). 
The membrane cutoff was nominally 25,000 daltons; the filtrates containing material that passed 
through the cones and the lysates were divided into aliquots and stored frozen at -70°C until use. 
Assay of Macrophage Chemotaxis Inhibitor.  Inhibition of in vivo macrophage accumulation 
was measured as previously described (2, 3).  Briefly, groups of four mice were injected subcuta- 
neously in the thigh with 0.2 ml of the tumor or control tissue filtrates. 24 h  later, the mice were 
injected intraperiteneally with 35 ~g of phytohemagglutinin (PHA)  (Burroughs Wellcome Co., 
Research Triangle Park,  N.C.) contained in 2 ml sterile, isotonic saline. 2 days later, the mice 
were killed, the peritoneal cavities were lavaged, and the total and differential white cell counts 
were determined for the individual mice. Results are expressed as: percent inhibition =  (1 -  (E/ 
C))  ×  100,  where E  equals the number of macrophages recovered from the peritoneal cavities of 
experimental mice treated with tumor or control tissue filtrates,  and C  equals the number of 
macrophages recovered from the peritoneal cavities of mice not treated with filtrates. 
Determination  of Relative Antigen Density on Tumor Cells.  The antigenic density on tumor 
cells was estimated using an indirect radioimmunoassay (RIA). In this RIA the amount of anti- 
tumor antibody bound was a  function of the amount of tumor antigen present on reacting cells. 
The details of the assay are published elsewhere (13). An antibody preparation containing mainly 
IgG1  (14)  was  incubated with  106  tumor  cells.  The cells were  washed  and reincubated in the 
presence of ~25I-rabbit anti-IgG1, then washed again and counted for ~25I. Conditions were chosen 
such that the amount of IgG1 bound was a  linear function of the amount of tumor cells present. 
The relative volume of individual tumor cells was calculated from the packed volume of a known 
number of tumor cells. The average volume of a  single cell was used to obtain the radius of the 
corresponding sphere. From this value, the surface area per tumor cell was calculated. Cell counts 
were performed in an hemocytometer. Line 1 tumor cells were >95% viable. Virulent tumor cell 
preparations contained <10% erythrocytes and were >95% viable. 
Results 
Growth Characteristics of  Attenuated Cells.  Aider introduction into culture, 
line 1 cells and subsequently, those of lines 2 and 3 were tested for their ability 
to grow in syngeneic hosts. A serial change in the growth pattern during tissue 
culture  adaptation  was  observed.  In  the  initial  stages  of culture,  the  cells 
behaved like the virulent tumor and were uniformly lethal to recipient animals. 
After a variable period in culture on the order of 4-8 wk, such cells displayed an 
attenuated phenotype. Fig. 1 illustrates the growth pattern of cells during this 
period.  In this experiment,  10  5 line  1 or virulent tumor cells were inoculated 
into the calf muscles of syngeneic C3H mice.  As expected,  the  virulent  cells 
gave rise to progressively growing tumors which eventually killed their hosts. PASTERNACK,  SNYDERMAN,  PIKE,  JOHNSON,  AND  SHIN  95 
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FIG.  1.  Growth of virulent and line 1 cells in syngeneic hosts. Groups of four mice were 
inoculated with either 10  ~ attenuated line 1 cells or 10  ~ virulent 6C3HED cells in the left 
calf muscle on day  0.  The  mean calf diameter -+  SEM  is plotted versus days of tumor 
growth. (O), attenuated; (A), virulent. 
The cultured line 1 cells, however, produced tumors that regressed in all mice 
tested. After regression, no recurrence was observed over an extended period of 
time.  Lines 2  and  3 behaved in  like  fashion to line  1 when  similarly  tested. 
After prolonged periods in culture exceeding 3 mo, the attenuated tumor cells 
failed to produce tumors  in  normal  hosts,  although  they succeeded in  suble- 
thally irradiated animals. 
The  regression  of the  line  1  tumors  was  dependent  upon  an  intact  host 
immune system. ATXBM mice were unable to cause tumors originating  from 
105  line  1  cells  to  regress.  The  data  in  Fig.  2  show  that  all  ATXBM  mice 
developed progressively growing tumors and  died,  whereas similarly  injected 
normal  C3H mice showed only transient  tumor growth.  The  attenuated  cells 
grew in ATXBM mice at a  rate approximately equal to the rate of growth of 
virulent cells in normal syngeneic mice. The requirement for an intact immune 
system implies that the regression of tumor growth is an immunologic rejection 
phenomenon  rather  than  an  alteration  of some intrinsic  growth properties of 
the tumor.  Other experiments  (data not shown) demonstrated  that once mice 
rejected tumors from cultured cells, they would not support tumor growth when 
subsequently challenged with either attenuated or virulent cells. 
Antigen Density Is Unchanged.  Since attenuated cells could grow in vivo in 
ATXBM mice at a  rate comparable to the usual growth rate of virulent cells, 
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FIG.  2.  Growth of line 1 cells in normal and ATXBM syngeneic hosts.  Groups of four 
normal and five ATXBM mice were inoculated with l0  s attenuated line 1 cells in the left 
calf muscle on day 0. By day 22, all normal mice had rejected their tumors and were alive. 
None of the ATXBM mice showed evidence of tumor rejection, and all were dead by day 22. 
The mean calf diameter -+ SEM is plotted versus days of tumor growth. (A), normal; (O), 
ATXBM. 
susceptibility of cultured cells to host defenses. The relative antigen density of 
the virulent and attenuated tumor cells was measured by RIA using syngeneic 
anti-tumor  antibody.  The  antibody was produced by injecting syngeneic mice 
intraperitoneally  with  ~10 7 cultured  cells  in  0.1  ml  Hanks'  balanced  salt 
solution emulsified in an equal volume of complete Freund's adjuvant at weekly 
intervals.  The antibody was collected as ascites fluid,  which was clarified by 
centrifugation  and used directly in the RIA. The results of the RIA shown in 
Table I  indicate that approximately the same amount of IgG1 was bound per 
unit of area on each tumor population.  The difference in the gross amount of 
IgG1 anti-tumor  antibody per cell could be explained  simply by differences in 
the surface areas of the two cell populations. 
Elaboration of Macrophage Chemotaxis Inhibitor.  Since no gross antigenic 
difference was found between the virulent and attenuated cells, an attempt was 
made to examine other functional immunologic differences between the tumor 
cells. In several experiments,  lysates were prepared from attenuated and from 
virulent cells. These were examined as unknown coded samples for their ability 
to inhibit  macrophage accumulation in vivo. The results of these experiments 
(summarized  in  Table  II)  indicate  that  cultured  cells,  which  displayed  an 
attenuated phenotype with respect to tumor growth, regularly failed to produce 
an  inhibitor  of macrophage  accumulation  in  vivo.  In  contrast,  the  virulent 
tumor was always found to produce this inhibitor. 
Macrophage Chemotaxis Inhibitor Restores Virulence to Cultured Cells.  In 
light of the preceding findings,  we sought to determine if MCI would reconsti- 
tute  the  virulent  tumor  phenotype  in  the  attenuated  tumor.  To  this  end, 
filtrates prepared from various tumors and control tissues were coded and tested 
for inhibitory activity as unknowns.  The tests were performed by inoculating PASTERNACK,  SNYDERMAN,  PIKE,  JOHNSON,  AND  SHIN 
TABLE  I 
Relative  Antigen Density:  Attenuated Versus Virulent  Tumor Cells 
97 
Experi- 
ment 
Anti-IgG1/tumor cell  Surface area/tumor cell  Anti-IgG1/surface  cell 
Virulent  Attenuated  Virulent  Attenuated  Virulent  Attenuated 
cpm  ~  cpm/~ 2 
I  4.2  x  10  -2  6.4  ×  10 -2  3.3  x  10  z  3.9  ×  10  2  1.3  ×  10 -4  1.6  ×  10 -4 
II  1.2  ×  10  -2  1.9  ×  10 -2  3.1  ×  10  2  4.4  x  10  2  3.9  x  10 -5  4.3  x  10  -5 
Line 1 cells  were used as attenuated cells  and freshly harvested 6C3HED  cells  were used as 
virulent cells.  The RIA and determination of  surface area were performed as described in the 
text.  The two experiments were performed on  separate days. 
TABLE  II 
An Inhibitor of Macrophage Accumulation in Virulent Neoplastic 
Cells 
Experiment  Lysate injected in  Accumulated perito- 
neal macrophages  Inhibition 
thigh  (106) 
% 
Virulent  4.0 _+ 0.6*  43 
Line 1  6.8 _+ 1.3  3 
None  7.0 _+ 0.2  - 
II  Virulent  2.3 _+ 0.8  65 
Line 1  6.1 _+ 2.0  6 
Line 2  5.6 -  0.7  14 
Line 25  5.3 __. 0.3  18 
Liver  7.3 _ 0.9  0 
Spleen  6.9 _+ 0.1  0 
None  6.5 +__ 0.7  - 
III  Virulent  3.9 ___ 0.9  38 
Line 3  6.0 _+ 0.5  5 
None  6.3 -!-- 1.8  - 
Coded tumor or control cell samples were sonicated, centrifuged, and the 
cell-free  lysates were tested for inhibition of macrophage accumulation in 
vivo in response to an intraporitoneal rejection'  ~  "  of PHA. Each lysate was 
tested in a group of four animals. 
*  -+ SEM. 
$ A second  sample was included in this experiment under a  different code 
letter. 
105  tumor  cells contained in a  mixture consisting of 50%  Hanks' solution and 
50% filtrate by volume. On the 2nd and 9th days after inoculation of the tumors, 
the  animals received an additional 0.2  ml of lysate, i.p.  Two separate experi- 
ments  are  summarized  in  Table  III.  The  results  clearly  show  that  filtrates 
prepared from tumors, which possess the ability to interfere with macrophage 
chemotaxis, were able to interfere with the rejection of the attenuated tumors. 
This effect was not specific, since preparations from several tumors were equally 
effective.  The filtrates prepared from normal tissues without malignant  char- 
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TABLe.  HI 
Reconstitution  of Virulent Phenotype in Attenuated Tumor 
Experiment  Filtrate source  Tumor  Mice reject- 
ing 
I  Liver  Line 2  4/4 
6C3HED  "  0/4 
Hepatoma*  "  4/4 
II  Liver  Line 3  4/4 
Hepatoma*  "  2/4 
BP8  "  2/4 
Spleen  "  4/4 
6C3HED  "  2/4 
Mice were challenged with 105  cultured cells  and treated as  described 
in the text.  The preparation of  the filtrates  from 6C3HED, the BP8 
fibrosarcoma,  hepatoma  129, and from normal  C3H  tissues was 
previously described (3). 
* The inconsistency of the results with the hepatoma has not been 
explained. 
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FIG.  3.  Growth  of line  1  cells  in  normal  and  tumor-bearing  hosts.  Four  mice  were 
inoculated with 10  s virulent 6C3HED  cells in the left calf muscle on day  -1.  On day 0, 
these and four untreated mice were inoculated with 10  s attenuated line 1 cells in the right 
calf muscle.  By day  19,  throe of four  untreated animals had rejected their tumors;  the 
fourth failed to reject and died. None of the animals bearing virulent tumors showed any 
evidence of rejection of either tumor. The mean calf diameter -+ SEM is plotted versus days 
of tumor growth. (0), untreated animals; (A), animals bearing virulent tumors. 
Virulent Phenotype Is Dominant.  The  growth pattern  of attenuated  cells 
may  be  influenced  by the  presence  of virulent  cells  elsewhere  in  the  same 
animal. As stated, with increasing time in culture, tumor cells become less able 
to  grow  in  normal  mice,  although  they  still  grow  in  sublethally  irradiated PASTERNACK,  SNYDERMAN,  PIKE,  JOHNSON,  AND  SHIN  99 
animals.  Rejection of tumor cells recently displaying the attenuated phenotype 
is impaired in a host bearing a  virulent neoplasm. In the experiment shown in 
Fig.  3,  three  of  four  animals  receiving  only  the  attenuated  tumor  cells 
eventually rejected their tumors;  the onset of rejection was between the  14th 
and 18th days. The failure of an occasional animal to reject attenuated cells was 
not an uncommon observation. These findings stand in marked contrast to the 
behavior  of the  attenuated  cells given  to hosts that  had  been  injected  1 day 
previously with an equal number of virulent tumor cells in the opposite leg. In 
these animals, no regression of the attenuated cells was seen. 
Discussion 
Previous studies established a  number of interesting  points concerning the 
behavior of tumor cells in tissue  culture.  A  number of workers showed that 
tumor cells maintained in tissue culture for prolonged periods of time may lose 
the ability to grow in the strains  of mice from which they originated  (15-17); 
these  observations  have  been  extensively  confirmed.  In  a  pertinent  study, 
Morgan et al.  (18) noted that  6C3HED behaved in this fashion,  and that the 
nontumorigenic, or attenuated cells were immunogenic in C3H mice, conferring 
resistance  to  a  challenge  with  virulent  cells.  Nontumorigenic  cells  become 
virulent only when injected in medium containing  sterile ascites fluid from a 
virulent Ehrlich-Lettr~  tumor.  Moore et al.  (19) made similar observations in 
an Ehrlich ascites tumor system. In their model, attenuated cells that failed to 
grow  in  adult  mice  produced  tumors  in  new  bern  animals,  suggesting  an 
immunologic basis for attenuation. 
In  our  work,  we  also  observed  that  6C3HED  behaved  in  this  manner; 
moreover, the use of an intramuscular site allowed us to detect tumor cells with 
tumorigenicity intermediates between virulence and complete attenuation. The 
failure  of ATXBM mice to reject the  attenuated  tumor cells shows that  the 
destruction of attenuated cells in vivo is immunologically mediated. Morgan et 
al.  (18)  were  unable  to  detect  growth  of  an  intraperitoneal  inoculum  of 
attenuated  cells  in  lethally  irradiated  mice; this  finding,  however,  might  be 
explained  on  the  basis  of local  factors  such  as  the  resident  population  of 
peritoneal macrophages. 
The  reasons  that  mice  are  more  resistant  to  tumor  cells  that  have  been 
serially passed in tissue culture have been previously unclear, but are of basic 
importance  for our understanding  of the mechanisms  of natural  resistance to 
neoplasms.  Our  studies  demonstrate  one  clear-cut  difference between  atten- 
uated  and  virulent  neoplastic cells.  Although  MCI has been found in all the 
virulent  murine  neoplasms  thus  far examined  (3,  7),  neither  normal  murine 
tissues nor the attenuated neoplastic cells contain this inhibitory activity. This 
observation was given additional biological significance in the present experi- 
ments where it was shown that the addition of the inhibitor reconstituted the 
malignant  phenotype  of the  attenuated  cells  in  vivo.  Although  it  remains 
possible that this was caused by a factor other than MCI present in the partially 
purified preparations,  it is clear that the effect was mediated by a factor unique 
to malignant  tissues.  These experiments showed that during passage in tissue 
culture,  the  neoplastic  cells  lost  their  ability  to  produce  an  inhibitor  of 
macrophage function,  suggesting a  causal relationship to the attenuated phe- 100  RELATION  OF  MACROPHAGE  CHEMOTAXIS  TO  TUMOR  IMMUNOGENICITY 
notype. A macrophage chemotaxis inhibitor has been previously demonstrated 
to circulate in the serum of mice with progressively growing tumors  (7).  This 
being the case,  it was important  to determine whether or not the attenuated 
cells would grow in mice already bearing virulent tumor cells.  With recently 
attenuated  tumor  cells,  some  factor  produced  by  the  virulent  tumor  cells 
prevented rejection and the mice developed progressive tumors at both sites of 
cell  administration;  the  attenuated  cells  had  no  obvious influence  upon  the 
virulent  tumor residing  in the  opposite leg.  Had concomitant  immunity  (20) 
been of significance in this experiment, the attenuated cells would have shown 
diminished  growth.  This is consistent with the observation by Eng et al.  (21) 
that  simultaneous  intraperitoneal  inoculation  of  attenuated  and  virulent 
6C3HED cells did not prevent ascites tumor formation. 
A  number of workers have shown that the macrophages may play a  central 
role in mediating immunological  resistance  to neoplasms  (9,  10),  and may be 
the  major  effectors  in  passive  immunotherapy  models  (11,  12).  This  former 
contention is supported by the studies presented herein, since interference with 
macrophage  function was shown to influence the ultimate  outcome of a  host- 
tumor relationship.  In  previous studies,  it  was  suggested that  the  ability  of 
neoplastic cells to subvert the host's macrophage function might be critical in 
determining whether or not the cells would grow successfully. It is possible that 
a  tumor's defense against the host's immune system might be based upon the 
ability of neoplastic cells to prevent an effective immunological response within 
the tumor (1-8). Conversely, some workers have shown but failed to explain the 
enhancement  of tumor growth by fluids from tumor-bearing animals  (18,  22). 
The studies reported here suggest that the ability of neoplastic cells to produce 
an inhibitor of macrophage chemotaxis might be the central event that allows 
them to overcome natural resistance and thereby grow successfully. Should this 
prove to be a  general  mechanism  whereby tumors  evade the  host's  immune 
response, the detection, isolation, and characterization of such factors may lead 
to  completely  new  approaches  to  immunodiagnosis  and  immunotherapy  of 
malignant disease. 
Summary 
Several  tissue  culture  lines  of 6C3HED,  a  murine  lymphoma,  were  more 
susceptible  to  immunologic  destruction  in  vivo  than  the  highly  virulent 
6C3HED line maintained  by serial intramuscular  transplantation.  The atten- 
uated  tissue  culture  cells  were rejected by normal  syngeneic  recipients,  but 
thymectomized mice were unable to reject attenuated cells.  In such mice, the 
growth rate of attenuated  cells was equivalent to the growth rate of virulent 
cells in normal syngeneic mice. The increased susceptibility of attenuated cells 
to  destruction  by  syngeneic  hosts  was  shown  to  correlate  with  decreased 
production by the tumor cells of a  macrophage chemotaxis inhibiter,  and not 
with altered antigen density. In addition, when inhibitor isolated from virulent 
cells was administered to mice challenged with attenuated cells, the latter cells 
became virulent in vivo. When attenuated and virulent cells were administered 
simultaneously in the same host, the attenuated cells were able to develop into 
progressively growing tumors.  The data suggest that the successful growth of PASTERNACK, SNYDERMAN, PIKE, JOHNSON,  AND  SHIN  101 
neoplastic cells in  normal animals may require tumor cells to produce factors 
which  subvert the  ability  of the  host  to  mobilize macrophages rapidly  at the 
tumor site. 
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